Tags: Cancer | FDA | rare | blood | cancer | leukemia | Pfizer

Drug for Rare Blood Cancer OK'd

Image: Drug for Rare Blood Cancer OK'd
(Copyright Fotolia)

Friday, 18 Aug 2017 08:49 AM

The U.S. Food and Drug Administration (FDA) said on Thursday it approved Pfizer Inc's treatment for a rare type of blood cancer.

The treatment, Besponsa, carries a boxed warning, the agency's severest form of warning reserved to caution against the most serious adverse events.

Besponsa was approved to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), a disease that will affect about 5,970 people in the United States this year and kill about 1,440, according to the National Cancer Institute.

B-cell precursor ALL is a rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell.

© 2017 Thomson/Reuters. All rights reserved.

 
1Like our page
2Share
Health-News
The U.S. Food and Drug Administration (FDA) said on Thursday it approved Pfizer Inc's treatment for a rare type of blood cancer.The treatment, Besponsa, carries a boxed warning, the agency's severest form of warning reserved to caution against the most serious adverse...
FDA, rare, blood, cancer, leukemia, Pfizer
111
2017-49-18
Friday, 18 Aug 2017 08:49 AM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved